Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation for Batch Consistency of Ad5-nCoV in Chinese Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. healthy participants aged 18 years and above who have not received COVID-19 vaccine.~2. The subjects can provide with informed consent and sign informed consent form (ICF).~4. The subjects are able to and willing to comply with the requirements of the clinical trial program and could complete the follow-up of the study.~5. Axillary temperature ≤ 37.0℃. 6. negative IgM and IgG against SARS-CoV-2 7. with BMI between18.5 to 30.0 8. No history of epidemiological contact with COVID-2019 9. have not been to medium or high risk areas in the past 21 days and have no history of departure.~10. be determined to be healthy by medical history, physical examination and clinical examination and meet the requirements for immunization of this product.~Exclusion criteria:~1. Medical history or family history of convulsion, epilepsy, encephalopathy and psychosis.~2. Allergic to any component of the research vaccines, or a history of hypersensitivity or serious reactions to vaccination.~3. Women with positive urine pregnancy test, pregnant or breast-feeding, or have a pregnancy plan in this study.~4. Suffering from acute febrile disease, infectious disease, or SARS infection history~5. Serious cardiovascular disease, such as arrhythmia, conduction block, myocardial infarction, severe hypertension, which cannot be controlled by medication (systolic blood pressure ≥180mmHg, diastolic blood pressure ≥110mmHg)~6. Have severe chronic diseases or unstable condition ( Grade 3 or higher as defined in the guidelines for the classification of adverse events in clinical trials for prophylactic vaccines), Such as diabetes, thyroid disease and so on.~7. Congenital or acquired angioedema / neuroedema.~8. had urticaria one year before this vaccination.~9. Asplenia or functional asplenia.~10. Thrombocytopenia or other clotting disorder (this may contraindicate intramuscular injection).~11. Faintng during acupuncture treatment~12. Received immunosuppressant therapy, antiallergic therapy, cytotoxic therapy, high dose inhaled corticosteroid over the past 6 months (excluding corticosteroid spray for allergic rhinitis, surface corticosteroid for acute non-complicated dermatitis, and corticosteroid with dose less than 20mg/ day)~13. Received blood products within 4 months before vaccination.~14. Received other investigational drugs within 1 month prior to receiving the investigational vaccines.~15. Received other live attenuated vaccines within 1 month prior to receiving the investigational vaccines.~16. Received subunit or inactivated vaccine within 14 days prior to receiving investigational vaccine.~17. Be receiving anti-tuberculosis treatment~18. Have the history of SARS-CoV-2 infection or COVID-19~19. Any medical, psychological, social or other conditions that, in the investigator's judgment, are inconsistent with the study protocol or affect the subjects' informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- batch 1 of Ad5-nCoV (Type: EXPERIMENTAL): Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202101001.
- batch 2 of Ad5-nCoV (Type: EXPERIMENTAL): Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202101002.
- batch 3 of Ad5-nCoV (Type: EXPERIMENTAL): Eligible subjects in both cohort were vaccinated with one injection of Ad5-nCoV, lot NCOV202102003.

Based on this trial design, predict the completion outcome and termination type (if applicable).